CCL

Összesen 4 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM071907
035-os BibID:(cikkazonosító)62 (WoS)000423384000001 (Scopus)85041107428
Első szerző:Agod Zsófia
Cím:Signaling Lymphocyte Activation Molecule Family 5 Enhances Autophagy and Fine-Tunes Cytokine Response in Monocyte-Derived Dendritic Cells via Stabilization of Interferon Regulatory Factor 8 / Zsofia Agod, Kitti Pazmandi, Dora Bencze, Gyorgy Vereb, Tamas Biro, Attila Szabo, Eva Rajnavolgyi, Attila Bacsi, Pablo Engel, Arpad Lanyi
Dátum:2018
ISSN:1664-3224
Megjegyzések:Signaling lymphocyte activation molecule family (SLAMF) receptors are essential regulators of innate and adaptive immune responses. The function of SLAMF5/CD84, a family member with almost ubiquitous expression within the hematopoietic lineage is poorly defined. In this paper we provide evidence that in human monocyte-derived dendritic cells (moDCs) SLAMF5 increases autophagy, a degradative pathway, which is highly active in dendritic cells (DCs) and plays a critical role in orchestration of the immune response. While investigating the underlying mechanism, we found that SLAMF5 inhibited proteolytic degradation of interferon regulatory factor 8 (IRF8) a master regulator of the autophagy process by a mechanism dependent on the E3 ubiquitin ligase tripartite motif-containing protein 21 (TRIM21). Furthermore, we demonstrate that SLAMF5 influences the ratio of CD1a+ cells in differentiating DCs and partakes in the regulation of IL?1?, IL?23 and IL?12 production in LPS/IFN??activated moDCs in a manner that is consistent with its effect on IRF8 stability. In summary, our experiments identified SLAMF5 as a novel cell surface receptor modulator of autophagy and revealed an unexpected link between the SLAMF and IRF8 signaling pathways, both implicated in multiple human pathologies.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
SLAMF5
Autophagy
Dendritic Cells
IRF8
TRIM21
IL?12p70
LPS/IFN?
Megjelenés:Frontiers in Immunology. - 9 (2018), p. 1-16. -
További szerzők:Pázmándi Kitti Linda (1984-) (molekuláris biológus, immunológus) Bencze Dóra (1992-) Vereb György (1965-) (biofizikus, orvos) Bíró Tamás (1968-) (élettanász) Szabó Attila (1981-) (molekuláris biológus, immunológus, filozófus) Rajnavölgyi Éva (1950-) (immunológus) Bácsi Attila (1967-) (immunológus) Engel, Pablo Lányi Árpád (1962-) (biológus, immunológus)
Pályázati támogatás:NKFIH K 81676
Egyéb
NKFIH K 109444
Egyéb
Romanian Ministry of Education, Executive Agency For Higher Education, Research, Development and Innovation Funding, PNCDI II, project no. 119/2014
Egyéb
GINOP-2.3.2-15-2016-00050
GINOP
COST Action BM1404 Mye-EUNITER
Egyéb
János Bolyai Research Scholarship from the Hungarian Academy of Sciences
Egyéb
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Szerző által megadott URL
DOI
Borító:

2.

001-es BibID:BIBFORM005686
Első szerző:Calpe, Silvia
Cím:The SLAM and SAP gene families control innate and adaptive immune responses / Silvia Calpe, Ninghai Wang, Xavier Romero, Scott B. Berger, Arpad Lanyi, Pablo Engel, Cox Terhorst
Dátum:2008
Megjegyzések:The nine SLAM-family genes, SLAMF1-9, a subfamily of the immunoglobulin superfamily, encode differentially expressed cell-surface receptors of hematopoietic cells. Engagement with their ligands, which are predominantly homotypic, leads to distinct signal transduction events, for instance those that occur in the T or NK cell immune synapse. Upon phosphorylation of one or more copies of a unique tyrosine-based signaling motif in their cytoplasmic tails, six of the SLAM receptors recruit the highly specific single SH2-domain adapters SLAM-associated protein (SAP), EAT-2A, and/or EAT-2B. These adapters in turn bind to the tyrosine kinase Fyn and/or other protein tyrosine kinases connecting the receptors to signal transduction networks. Individuals deficient in the SAP gene, SH2D1A, develop an immunodeficiency syndrome: X-linked lympho-proliferative disease. In addition to operating in the immune synapse, SLAM receptors initiate or partake in multiple effector functions of hematopoietic cells, for example, neutrophil and macrophage killing and platelet aggregation. Here we discuss the current understanding of the structure and function of these recently discovered receptors and adapter molecules in the regulation of adaptive and innate immune responses.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Linked Lymphoproliferative-Disease
Lymphocitic Activation Molecule
Epstein-Barr-Virus
Natural-Killer-Cells
Huan NK Cells
Systemic-Lupus-Erythematosus
CD8(+) T-Cells
Common Variable Immunodeficiency
Human B-Lymphocytes
Receptor 2B4 CD244
Megjelenés:Advances in Immunology. - 97 (2008), p. 177-250. -
További szerzők:Wang, Ninghai Romero, Xavier Berger, Scott B. Lányi Árpád (1962-) (biológus, immunológus) Engel, Pablo Terhorst, Cox
Internet cím:elektronikus változat
DOI
elektronikus változat
Borító:

3.

001-es BibID:BIBFORM081249
035-os BibID:(PMID)30522694
Első szerző:Cuenca, Marta
Cím:CD84 cell surface signaling molecule : an emerging biomarker and target for cancer and autoimmune disorders / Marta Cuenca, Jordi Sintes, Árpád Lányi, Pablo Engel
Dátum:2019
ISSN:1521-6616
Megjegyzések:CD84 (SLAMF5) is a member of the SLAM family of cell-surface immunoreceptors. Broadly expressed on most immune cell subsets, CD84 functions as a homophilic adhesion molecule, whose signaling can activate or inhibit leukocyte function depending on the cell type and its stage of activation or differentiation. CD84-mediated signaling regulates diverse immunological processes, including T cell cytokine secretion, natural killer cell cytotoxicity, monocyte activation, autophagy, cognate T:B interactions, and B cell tolerance at the germinal center checkpoint. Recently, alterations in CD84 have been related to autoimmune and lymphoproliferative disorders. Specific allelic variations in CD84 are associated with autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. In chronic lymphocytic leukemia, CD84 mediates intrinsic and stroma-induced survival of malignant cells. In this review, we describe our current understanding of the structure and function of CD84 and its potential role as a therapeutic target and biomarker in inflammatory autoimmune disorders and cancer.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Autoimmune disorders
Autophagy
CD84
Chronic lymphocytic leukemia (CLL)
Disease biomarkers
Germinal center (GC)
SLAM family receptors
Megjelenés:Clinical Immunology. - 204 (2019), p. 43-49. -
További szerzők:Sintes, Jordi Lányi Árpád (1962-) (biológus, immunológus) Engel, Pablo
Pályázati támogatás:K-109444
NKFIH
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM065580
Első szerző:Morra, Massimo
Cím:Characterization of SH2D1A Missense Mutations Identified in X-linked Lymphoproliferative Disease Patients / Massimo Morra, Maria Simarro-Grande, Margarita Martin, Alice Siau-In Chen, Arpad Lanyi, Olin Silander, Silvia Calpe, Jack Davis, Tony Pawson, Michael J. Eck, Janos Sumegi, Pablo Engel, Shun-Cheng Li, Cox Terhorsta
Dátum:2001
ISSN:0021-9258 1083-351X
Megjegyzések:X-linked lymphoproliferative disease (XLP) is a primary immunodeficiency characterized by extreme susceptibility to Epstein-Barr virus. The XLP disease gene product SH2D1A (SAP) interacts via its SH2 domain with a motif (TIYXXV) present in the cytoplasmic tail of the cell-surface receptors CD150/SLAM, CD84, CD229/Ly-9, and CD244/2B4. Characteristically, the SH2D1A three-pronged interaction with Tyr(281) of CD150 can occur in absence of phosphorylation. Here we analyze the effect of SH2D1A protein missense mutations identified in 10 XLP families. Two sets of mutants were found: (i) mutants with a marked decreased protein half-life (e.g. Y7C, S28R, Q99P, P101L, V102G, and X129R) and (ii) mutants with structural changes that differently affect the interaction with the four receptors. In the second group, mutations that disrupt the interaction between the SH2D1A hydrophobic cleft and Val +3 of its binding motif (e.g. T68I) and mutations that interfere with the SH2D1A phosphotyrosine-binding pocket (e.g. C42W) abrogated SH2D1A binding to all four receptors. Surprisingly, a mutation in SH2D1A able to interfere with Thr -2 of the CD150 binding motif (mutant T53I) severely impaired non-phosphotyrosine interactions while preserving unaffected the binding of SH2D1A to phosphorylated CD150. Mutant T53I, however, did not bind to CD229 and CD224, suggesting that SH2D1A controls several critical signaling pathways in T and natural killer cells. Because no correlation is present between identified types of mutations and XLP patient clinical presentation, additional unidentified genetic or environmental factors must play a strong role in XLP disease manifestations.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal Of Biological Chemistry 276 : 39 (2001), p. 36809-36816. -
További szerzők:Simarro-Grande, Maria Martin, Margarita Chen, Alice Siau-In Lányi Árpád (1962-) (biológus, immunológus) Silander, Olin Calpe, Silvia Davis, Jack Pawson, Tony Eck, Michael J. Sümegi János Engel, Pablo Li, Shun-Cheng Terhorst, Cox
Pályázati támogatás:PO1-AI-35714
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1